Skip to main navigation

Top

Skip to main content

About Us

About Us
Rare Diseases

Rare Defined Diseases
Pipeline

Pipeline
Our Medicines

Our Medicines
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Press Releases

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Jun 01, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Read More

PDF Version

May 29, 2026

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Read More

PDF Version

May 22, 2026

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

Read More

PDF Version

May 12, 2026

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Read More

PDF Version

May 12, 2026

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Read More

PDF Version

Apr 29, 2026

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Read More

PDF Version

Apr 06, 2026

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Read More

PDF Version

Mar 31, 2026

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Read More

PDF Version

Mar 02, 2026

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Read More

PDF Version

Feb 12, 2026

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Read More

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on X.

Connect on LinkedIn

Follow us on X

Contact
About Us
Partner Opportunities
Careers

Agios Pharmaceuticals, Inc. © 2026

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use